Clinical Trial Update: Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of checkpoint inhibition after autologous stem cell transplantation for patients at high risk of post-transplant recurrence was terminated, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Multiple Myeloma, Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-07-25